Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotic Policy Solutions An Ocean Apart Between U.S., EU

This article was originally published in The Pink Sheet Daily

Executive Summary

Governments are taking on different initiatives to solve the problem of developing products to address worries about drug-resistant bacteria. The EU is helping to fund trials, while the U.S. is offer extended exclusivity.

You may also be interested in...



Cubist Sets Sights On European Antibiotics Market With Zurich Move: A Conversation With Patrick Vink

Cubist recently has seen its key antibiotic Cubicin become a blockbuster in the U.S. It is determined to take this success, backed by a flourishing pipeline, to answer Europe's call for products to fight antimicrobial resistance.

View From ICAAC: How Higher Prices Can Help Save Antibiotic R&D

At the annual anti-infectives meeting, experts consider revamping the business model to spur development of novel antibiotics, with cooperation of regulators in Europe and U.S.

FDA Antibiotic Legislation Should Focus On Criteria, Not Bacteria, Woodcock Says

Congress should allow the agency to determine which drug-resistant bacteria sponsors should target in order to earn incentives for antibiotic development, rather than list specific pathogens, CDER Director Janet Woodcock suggested to a House panel March 8. The window to change the GAIN Act appears to be closing, though.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel